Mp85-14 aberrant methylation of ccnd2 is associated with loss of expression and tumor pathylogical subtypes in renal cell cancer
lu wang,yu fan,yun cui,yang yang,jin dong sheng,qian zhang,jie jin
DOI: https://doi.org/10.1016/j.juro.2016.02.2280
2016-01-01
Abstract:You have accessJournal of UrologyKidney Cancer: Basic Research & Pathophysiology II1 Apr 2016MP85-14 ABERRANT METHYLATION OF CCND2 IS ASSOCIATED WITH LOSS OF EXPRESSION AND TUMOR PATHYLOGICAL SUBTYPES IN RENAL CELL CANCER lu wang, yu fan, yun cui, yang yang, jin dong sheng, qian zhang, and jie jin lu wanglu wang More articles by this author , yu fanyu fan More articles by this author , yun cuiyun cui More articles by this author , yang yangyang yang More articles by this author , jin dong shengjin dong sheng More articles by this author , qian zhangqian zhang More articles by this author , and jie jinjie jin More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2280AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES CCND2 plays a pivotal role in cell cycle regulation and its abnormal expression has been observed in several human malignancies [1-5]. Owing to the controversial role of CCND2 deregulation in carcinogenesis, we aim to explore the expression status and its related regulation mechanism in renal cell cancer (RCC). METHODS Semi-quantitative RT-PCR and quantitative RT-PCR were possessed to assess the mRNA expression of CCND2 in 7 RCC cell lines, 2 normal kidney cell lines and 24 paired RCC tissues. To further check the expression of CCND2, immunohistochemistry was used to verify the protein expression of CCND2 in 45 paired RCC paraffin sections. Then we use Methylation specific PCR and Bisulfite Genomic Sequencing to observe the methylation status of CCND2 in both cell lines, 102 primary RCC tissues and 23 RCC surgical margin tissues. To explain the relation between CCND2 expression level and its promoter hypermethylation, we next used RT-PCR and qRT-PCR to check the expression status after demethylation treatment with AZA and TSA. RESULTS The mRNA expression level of CCND2 was significantly down-regulated in RCC cell lines(6/7) and 24 paired primary RCC tissues compared with nontumorigenic cells and adjacent normal tissues. The results of ICH further confirmed the down-regulation of CCND2 in RCC tissues in protein level. Then we analysed the promoter methylation and its expression, we found that the promoter methylation level of CCND2 was much higher in RCC cell lines than nontumorigenic cell lines. Demethylation treatment with AZA and TSA could partly restore the expression of CCND2, which further confirm that the absence of CCND2 was mainly caused by its promoter aberrant methylation. By analyzing the correlation between 102 clinical RCC samples and 23 RCC surgical margin tissues, we found CCND2 was methylated in 29/102(28%) RCC samples and 2/23 (8.7%) surgical margin tissues. We also found that the methylation of CCND2 was associated with RCC pathologic subtypes. CONCLUSIONS In conclusion, our study imply that CCND2 was frequently down-regulated in both RCC cell lines and primary RCC tissues, which was mainly caused by its promoter aberrant methylation. We also explain the relationship between its promoter methylation and clinical information. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e1103 Advertisement Copyright & Permissions© 2016MetricsAuthor Information lu wang More articles by this author yu fan More articles by this author yun cui More articles by this author yang yang More articles by this author jin dong sheng More articles by this author qian zhang More articles by this author jie jin More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...